CASI’s assets include a small portfolio of FDA-approved and FDA-pending ANDAs for generic products.
Entecavir tablets, Tenofovir disoproxil fumarate (TDF) tablets, Cilostazol tablets – 50mg, Cilostazol tablets – 100mg, Ondansetron HCL tablets, and Tizanidine tablets
CASI Pharmaceuticals, Inc. is a NASDAQ-listed biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products. CASI has built a portfolio that includes approved and investigational assets. We conduct our commercial, clinical operations and R&D activities through our subsidiaries in China and branch office in Rockville, Maryland.
EVOMELA® (melphalan) for Injection is proprietary to Acrotech Biopharma LLC and its affiliates.
© 2023 CASI Pharmaceuticals Inc.
All Rights Reserved.